几年的努力奋斗，科学实验家们在针对性几个恶性瘤恶性癌病的KRAS变异方位已是具有了多向新况:After decades of efforts, scientists have made progress into targeting KRAS mutations in several malignancies.在1968年, Ha-Ras 和 Ki-Ras可逆录木马病毒转换成什么是基因被察觉，他们对应着的猿类RAS皇室家族HRAS和KRAS于1982年被察觉.In 1967, Ha-Ras and Ki-Ras retroviral transforming genes were discovered.Their human counterparts,Ha-Ras and Ki-Ras ,were discovered in 1982.KRAS 与肺腺癌的内在联系于1983年被第一次 表述，这类年KRAS 变动在肺腺癌中就已有多选突破。变动的KRAS被维持性提高，并导致维持的河流下游数字信号传递和癌肿发生。The relationship between KRAS and lung cancer was described in 1984,KRAS mutation in lung cancer has progressed.Mutant KRAS is constitutively activated and leads to persistent downstream signalling and oncogenesis.在2014年伴随对KRAS动物学的熟悉加强和治疗中药构思水平的更行，完美家们在GDP紧密紧密联系的突变性型KRAS G12C 蛋白质中发现了半胱氨酸治疗中药紧密紧密联系袋。In 2013 improved understanding of KRAS biology and newer drug designing technologies led to crucial discovery of a cysteins drug binding pocket in GDP-bound mutant KRAS G12C protein.在202一年，科学有效家们取得胜利开发建设出中医变动型KRAS G12C 的共价缓和剂。202一年介绍，Sotorasib提升FDA批准书，适用于手术治疗KRAS G12C变动的NSCLC，她是1、个应用的KRAS G12C缓和剂，现在另外还有更高口服药物也正在创新中。In 2021,covalent inhibitors that block mutant KRAS G12C were successfully developed.In May 2021 the US FDA granted accelerated approval to Sotorasib(1st KRAS G12C inhibitor)，for the treatment of adults with advanced NSCLC with KRAS G12C mutation.Sotorasib was the first KRAS G12C inhibitor to be approved，with several more in the pipeline。
涉及到最新报道
